Evidence map›Paper›PMID 37503298›Full record

ArticlebioRxiv : the preprint server for biology2024

Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus.

Natalia E Ketaren, Fred D Mast, Peter C Fridy, Jean Paul Olivier, Tanmoy Sanyal, Andrej Sali, Brian T Chait, Michael P Rout, John D Aitchison

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Natalia E KetarenLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, New York 10065, USA.ORCID 0000-0002-7869-6162
Fred D MastCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington 98109, USA.ORCID 0000-0002-2177-6647
Peter C FridyLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, New York 10065, USA.ORCID 0000-0002-8208-9154
Jean Paul OlivierCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington 98109, USA.ORCID 0000-0002-2197-271X
Tanmoy SanyalDepartment of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, Byers Hall, 1700 4th Street, Suite 503B, University of California, San Francisco, San Francisco, California 94143, USA.ORCID 0000-0002-6009-9431
Andrej SaliDepartment of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, Byers Hall, 1700 4th Street, Suite 503B, University of California, San Francisco, San Francisco, California 94143, USA.ORCID 0000-0003-0435-6197
Brian T ChaitLaboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, New York 10065, USA.ORCID 0000-0003-3524-557X
Michael P RoutLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, New York 10065, USA.ORCID 0000-0003-2010-706X
John D AitchisonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington 98109, USA.ORCID 0000-0002-9153-6497
Rockefeller University · USInfectious Disease Research Institute · USQB3 · US

Funding

TR&D Project 4. The Imaging Stage: Multiscale Spatiotemporal Modeling of Macromolecular Systems in Cellular NeighborhoodsP41GM109824 · NIGMS · ROCKEFELLER UNIVERSITY · PI ROUT, MICHAEL P · 2014 to 2023
$18.8M
IMP: Software for Hybrid Determination of Macromolecular Assembly StructuresR01GM083960 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SALI, ANDREJ · 2008 to 2024
$5.2M
NIGMS NIH HHS P41 GM109824NIGMS NIH HHS R01 GM083960
6 · The paper itself

Abstract

To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost significant efficacy against the latest circulating variants. As SARS-CoV-2 omicron sublineages account for over 90% of COVID-19 infections, evasion of immune responses generated by vaccination or exposure to previous variants poses a significant challenge. A compelling new therapeutic strategy against SARS-CoV-2 is that of single domain antibodies, termed nanobodies, which address certain limitations of monoclonal antibodies. Here we demonstrate that our high-affinity nanobody repertoire, generated against wild-type SARS-CoV-2 spike protein (Mast, Fridy et al. 2021), remains effective against variants of concern, including omicron BA.4/BA.5; a subset is predicted to counter resistance in emerging XBB and BQ.1.1 sublineages. Furthermore, we reveal the synergistic potential of nanobody cocktails in neutralizing emerging variants. Our study highlights the power of nanobody technology as a versatile therapeutic and diagnostic tool to combat rapidly evolving infectious diseases such as SARS-CoV-2.

Identifiers

PMID37503298
PMCPMC10369967
OpenAlexW4384283029

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.